Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Bioavailability Enhancement: Drug Stability Enhancement and GI Retention01:05

Bioavailability Enhancement: Drug Stability Enhancement and GI Retention

281
Improving a drug's stability in the gastrointestinal (GI) tract is paramount for enhancing its bioavailability and therapeutic effectiveness. Various strategies are employed to protect the drug from the harsh gastric milieu and to ensure its release and absorption at the desired site within the GI tract.Polymer coatings are one such method used to shield drugs from the stomach's acidic environment. By preventing premature drug release, these coatings improve the bioavailability of unstable...
281
Factors Affecting Dissolution: Drug Permeability, Stability and Stereochemistry01:20

Factors Affecting Dissolution: Drug Permeability, Stability and Stereochemistry

630
Orally administered drugs primarily enter the systemic circulation via passive diffusion through the intestinal membranes. The drug's absorption is influenced by drug stability in the gastrointestinal GI tract, membrane permeability, the surface area available for absorption, luminal drug concentration, and residence time in the lumen. Drug permeability can be enhanced by adjusting the lipophilicity, polarity, or molecular size of the drug, promoting its passive transport across intestinal...
630
Modified-Release Drug Delivery Systems: Overview01:19

Modified-Release Drug Delivery Systems: Overview

72
Modified-release dosage forms are designed to address the limitations of drugs with short biological half-lives. These forms maintain stable therapeutic drug concentrations over extended periods, reducing the need for frequent dosing. A consistent drug level helps minimize peak-trough fluctuations, which can reduce adverse effects, lower the risk of drug resistance, and improve overall treatment effectiveness.One common type of modified-release form is the extended-release (ER) formulation. ER...
72
Modified-Release Drug Delivery Systems: Influencing Factors01:20

Modified-Release Drug Delivery Systems: Influencing Factors

83
Modified-release drug delivery systems are designed to optimize the therapeutic effect of drugs by minimizing side effects, reducing the dosage required, and controlling drug release to align with pharmacokinetic and pharmacodynamic needs. The system depends on two key factors: the drug's release from the formulation and its movement through the body to the target site. Unlike conventional dosage forms, where absorption is the limiting step, the rate of drug release is the key determinant in...
83
Ophthalmic Drug Delivery Systems01:23

Ophthalmic Drug Delivery Systems

107
Ophthalmic drug delivery faces major limitations due to poor absorption across the corneal membrane. This process is primarily driven by diffusion and is influenced by two main factors: the physicochemical properties of the drug and tear drainage. Most ophthalmic drugs, such as pilocarpine, epinephrine, atropine, and local anesthetics, are weak bases. They are typically formulated at an acidic pH to enhance chemical stability. However, this leads to high ionization, reducing their ability to...
107
Oral Drug Delivery Systems: Delayed-Release Systems01:11

Oral Drug Delivery Systems: Delayed-Release Systems

78
Delayed-release drug delivery systems are specialized pharmaceutical formulations designed to postpone the release of active compounds until the drug reaches a specific region of the gastrointestinal (GI) tract, typically the intestine. These systems are essential for drugs that may cause gastric irritation, are unstable in acidic environments, or need to exert therapeutic effects locally in the intestinal or colonic regions.The core feature of delayed-release systems is the use of enteric...
78

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Spore-Based Biocomposite Thermoplastic Polyesters with Enhanced Toughness and Programmable Disintegration.

bioRxiv : the preprint server for biology·2026
Same author

Doxycycline release from cyclodextrin oligomer-containing collagen gels.

Journal of controlled release : official journal of the Controlled Release Society·2026
Same author

DIW Printing of PEDOT:PSS on Living Plants for Biohybrid Systems.

ACS omega·2026
Same author

Fecal microbiota transplantation in mice improves bone material properties through altered mineral quality.

JBMR plus·2025
Same author

Guided-Mode-Resonant Colorimetric Metasurfaces for All-Optical and Nondestructive Structural Characterization of Polymeric Nanofibers.

Nano letters·2025
Same author

A responsive living material prepared by diffusion reveals extracellular enzyme activity of cyanobacteria.

Proceedings of the National Academy of Sciences of the United States of America·2025

Related Experiment Video

Updated: Mar 3, 2026

Identification of Pharmaceuticals in The Aquatic Environment Using HPLC-ESI-Q-TOF-MS and Elimination of Erythromycin Through Photo-Induced Degradation
05:46

Identification of Pharmaceuticals in The Aquatic Environment Using HPLC-ESI-Q-TOF-MS and Elimination of Erythromycin Through Photo-Induced Degradation

Published on: August 1, 2018

13.7K

Erythromycin Modification That Improves Its Acidic Stability while Optimizing It for Local Drug Delivery.

Erika L Cyphert1, Jaqueline D Wallat2, Jonathan K Pokorski3

  • 1Department of Biomedical Engineering, Case Western Reserve University, 10900 Euclid Avenue, Cleveland, OH 44106, USA. elc50@case.edu.

Antibiotics (Basel, Switzerland)
|April 26, 2017
PubMed
Summary

Researchers developed a new erythromycin conjugate for better stability and targeted delivery. This approach improves bioavailability and reduces side effects by releasing the antibiotic at infection sites.

Keywords:
adamantanecyclodextrinerythromycinhydrophobicinfectionpH-responsivepH-sensitivepolymer

More Related Videos

The Logic, Experimental Steps, and Potential of Heterologous Natural Product Biosynthesis Featuring the Complex Antibiotic Erythromycin A Produced Through E. coli
10:41

The Logic, Experimental Steps, and Potential of Heterologous Natural Product Biosynthesis Featuring the Complex Antibiotic Erythromycin A Produced Through E. coli

Published on: January 13, 2013

19.1K
Ex Vivo Red Blood Cell Hemolysis Assay for the Evaluation of pH-responsive Endosomolytic Agents for Cytosolic Delivery of Biomacromolecular Drugs
11:12

Ex Vivo Red Blood Cell Hemolysis Assay for the Evaluation of pH-responsive Endosomolytic Agents for Cytosolic Delivery of Biomacromolecular Drugs

Published on: March 9, 2013

35.7K

Related Experiment Videos

Last Updated: Mar 3, 2026

Identification of Pharmaceuticals in The Aquatic Environment Using HPLC-ESI-Q-TOF-MS and Elimination of Erythromycin Through Photo-Induced Degradation
05:46

Identification of Pharmaceuticals in The Aquatic Environment Using HPLC-ESI-Q-TOF-MS and Elimination of Erythromycin Through Photo-Induced Degradation

Published on: August 1, 2018

13.7K
The Logic, Experimental Steps, and Potential of Heterologous Natural Product Biosynthesis Featuring the Complex Antibiotic Erythromycin A Produced Through E. coli
10:41

The Logic, Experimental Steps, and Potential of Heterologous Natural Product Biosynthesis Featuring the Complex Antibiotic Erythromycin A Produced Through E. coli

Published on: January 13, 2013

19.1K
Ex Vivo Red Blood Cell Hemolysis Assay for the Evaluation of pH-responsive Endosomolytic Agents for Cytosolic Delivery of Biomacromolecular Drugs
11:12

Ex Vivo Red Blood Cell Hemolysis Assay for the Evaluation of pH-responsive Endosomolytic Agents for Cytosolic Delivery of Biomacromolecular Drugs

Published on: March 9, 2013

35.7K

Area of Science:

  • Medicinal Chemistry
  • Organic Synthesis
  • Pharmacology

Background:

  • Erythromycin's efficacy is limited by instability and poor bioavailability in acidic environments.
  • Existing analogs like azithromycin and clarithromycin offer improved stability but not optimal targeted release.
  • Infection sites, particularly those caused by Staphylococcus aureus, exhibit slightly acidic conditions.

Purpose of the Study:

  • To develop a novel erythromycin conjugate with enhanced pH stability and bioavailability.
  • To achieve preferential drug release at acidic infection sites for targeted therapy.
  • To create a drug delivery system that reduces systemic toxicity and off-target effects.

Main Methods:

  • Covalent attachment of adamantane-1-carbohydrazide to erythromycin using a pH-degradable hydrazone bond.
  • Synthesis of the erythromycin conjugate designed for hydrolysis in acidic conditions.
  • Evaluation of the conjugate's stability, hydrophobicity, and antimicrobial activity.

Main Results:

  • Successful synthesis of a pH-cleavable erythromycin conjugate.
  • The conjugate demonstrated improved stability in acidic conditions compared to native erythromycin.
  • The adamantane group facilitated interaction with drug delivery systems, enabling targeted release.
  • The conjugate retained erythromycin's antimicrobial activity while enhancing its bioavailability.

Conclusions:

  • The novel erythromycin conjugate offers improved pH stability and targeted drug delivery.
  • This strategy enhances erythromycin bioavailability and reduces potential systemic side effects.
  • The pH-cleavable linkage ensures localized drug release at infection sites, improving therapeutic outcomes.